You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The group's CureCloud initiative combines patient health data with sequencing data from its liquid biopsy test to help oncologists select treatments.
Transcriptomic and multi-omic data spanning more than 10,000 samples helped map "immunogenomic" interactions that may inform treatment outcomes and targets.
GNS Healthcare will apply its AI and simulation technology to data from the CoMMpass study in search of insights on disease progression and drug response.
A single-cell RNA sequencing analysis suggests progression to multiple myeloma involves shifts in immune cell representation and activity in the microenvironment.
Adaptive said that Q4 clinical testing volume for its ClonoSeq sequencing assay for minimal residual disease increased 66 percent to 3,218 tests.
The study's goal is to measure the success rate of SkylineDx's multiple myeloma test in a real-world setting compared to the hospital's current standard.
The first phase of the study to evaluate Telo Genomics' telomere analytics as a prognostic solution for multiple myeloma is expected to launch in Q1 2020.
Amgen's latest deal with a pharma company will see its clonoSeq assay used for minimal residual disease testing in a clinical trial for venetoclax.
The partners will use Adaptive's ClonoSeq assay to assess minimal residual disease in several of Amgen's hematology drug development programs.
The immune sequencing firm is working on kit-ifying its two existing tests, as well as developing a second clinical test and expanding the label for clonoSeq.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.